Palbocicilib

ApprovedSmall molecule

Palbocicilib is one of 27 small molecule programs targeting Papillary Renal Cell Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Papillary Renal Cell CarcinomaActive, not recruiting

Breast CancerActive, not recruiting

Papillary Renal Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Breast CancerApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Palbocicilib

NNational Cancer Institute (NCI)

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Adenocard

Astellas

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Acupan

YYonsei University

Preclinical

1 8

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Ablavar

LLantheus Medical Imaging

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Papillary Renal Cell Carcinoma

NCT05665361

Clinical

Trials by Indication[1]

Papillary Renal Cell Carcinoma1 trial

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT05665361·100 enrolled

Breast Cancer1 trial

Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt

Completed·—·Phase 4·NCT07487129·206 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Palbocicilib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Palbocicilib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Palbocicilib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Cancer Institute (NCI)

Palbocicilib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Papillary Renal Cell Carcinoma1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News